drugset
drugset / Trial / NCT05964257

To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy

NCT05964257 ↗

Phase 3 Active not recruiting 188 enrolled Huons Biopharma
RandomizedParallel-groupDouble-blindTreatment

Summary

A double-blind, randomized, placebo-controlled, multi-center, phase III study to evaluate the efficacy and safety of LIZTOX in subjects with benign Masseteric hypertrophy

Timeline

Start
2023-07-25
Primary completion
2024-03-07
Completion
2025-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic — Intramuscular

Indications

masticatory muscles, hypertrophy of